McAllen mom battling COVID-19 now in stable condition after son asked Gov. Abbott for help
2 months 3 days 23 hours ago
Wednesday, February 10 2021
Feb 10, 2021
February 10, 2021 1:56 PM
February 10, 2021
in
News - Local
By: KRGV Digital
Share:
Nearly two weeks ago, 14-year-old Emilian Sosa of McAllen wrote a heartfelt letter to Gov. Greg Abbott asking for help to get his critically ill mother a COVID-19 treatment unavailable in the Valley.
In his letter the teen asked Abbott for help getting his mother to a Houston hospital to save her life, and he did.
Erika Calderon was transferred to Memorial Hermann Texas Medical Center in Houston and is now in stable condition, showing encouraging signs by squeezing her hand and opening her eyes.
McAllen teen writes letter to Abbott in an effort to help his mom survive COVID-19
1 month 3 weeks 1 day ago
Friday, January 29 2021
Jan 29, 2021
January 29, 2021 7:56 AM
January 29, 2021
in
News - Local
Share:
A McAllen teenager wrote a letter to Gov. Abbott urging him to help his mother who has been battling COVID-19.
Emilian Sosa, 14 , of McAllen said he and his mom were exposed to COVID-19 on Christmas Eve. He tested negative, but his mother tested positive.
After her diagnosis, her condition slowly deteriorated. Emilian Sosa began looking for other options to help and came across extracorporeal member oxygenation or ECMO a treatment used on COVID-19 patients that helps with cardiac and respiratory support to the heart and lungs. However, this treatment wasn t available in the Rio Grande Valley.
McAllen woman to receive life-saving COVID-19 therapy after her son writes to Gov. Abbott
The therapy is available in major Texas cities, like Dallas and Houston, but has not been available at the hospital in the Rio Grande Valley where the woman has spent the past few weeks fighting the virus.
Memorial Hermann-Texas Medical Center in Houston is one of the U.S. hospitals Walmart has identified as a center for excellence, a program it created where it offers employees the option to travel to hospitals specializing in certain surgeries.(Michael Ciaglo / Houston Chronicle)
A McAllen woman hospitalized with COVID-19 is set to receive a life-saving COVID-19 treatment after her son wrote a letter to Gov. Greg Abbott that went viral online.
E-Mail
IMAGE: John Harvin, MD, led a team of physician-researchers to identify an opioid-minimizing pain management strategy for patients with acute trauma. view more
Credit: Cody Duty/UTHealth
A pain management regimen comprised mostly of over-the-counter medication reduced opioid exposure in trauma patients while achieving equal levels of pain control, according to a new study by physician-researchers at The University of Texas Health Science Center at Houston (UTHealth.)
Results of the study, which was conducted at the Red Duke Trauma Institute at Memorial Hermann-Texas Medical Center, were published today in the
Journal of American College of Surgeons. The research shows us that seriously injured people with acute pain can effectively be treated with an opioid-minimizing strategy, said John Harvin, MD, MS, associate professor in the Department of Surgery at McGovern Medical School at UTHealth and first and corresponding author of the study. Narcotics ar
Researchers receive $5.1 million to expand clinical trial of drug to prevent ARDS in COVID-19 patients
Researchers evaluating whether an investigational oral drug, vadadustat, can help prevent acute respiratory distress syndrome (ARDS) in COVID-19 patients were awarded $5.1 million in funding from the U.S. Department of Defense (DOD) to expand the Phase II clinical trial at The University of Texas Health Science Center at HoustonQ (UTHealth).
Vadadustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI, designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of HIF, which can lead to improved oxygen delivery to tissues. Stabilization of HIF can help to dampen alveolar inflammation, a key problem that patients with COVID-19-associated lung disease are facing when they develop ARDS. The drug is investigational in the U.S. but has been